World Lung Cancer Day 2026: Coordinate Awareness Across the Care System

Lung cancer care exposes the weaknesses between departments. A primary care practice may identify a person who could benefit from a screening discussion, but imaging capacity may be distant. A scan may be completed, but its result may sit in an inbox without an assigned next action. A suspicious finding may reach pulmonology, yet prior images, authorization, transportation, or specialty capacity may delay resolution. A biopsy may establish a diagnosis but provide too little material for the tests that guide treatment. An oncology visit may occur while molecular results remain pending. Each team can complete its own task and the patient can still experience a fragmented pathway.

The executive mandate is not to dictate clinical choices. It is to create reliable operating conditions around those choices. Leaders can ensure that requests enter a traceable queue, ownership survives handoffs, results close, capacity is matched to expected demand, exceptions escalate, and people know what will happen next. They can also ensure that the pathway is measured across access, timeliness, safety, experience, equity, workforce, and outcomes rather than reduced to the number of scans performed.

Screening volume is an incomplete success measure. A program that expands scans without monitoring diagnostic-resolution capacity can move delay downstream. In an England-wide observational analysis, regions participating in a population-based multicancer screening trial had a modest, temporary increase in the proportion of referred patients waiting more than 28 days for diagnostic resolution relative to nonparticipating regions.¹⁰ The analysis does not prove that every delay was caused by the trial, and its multicancer context is not identical to lung cancer screening. It does show why leaders should pair screening growth with capacity and delay measures for the diagnostic services that follow.

Eligibility estimates should therefore become workload scenarios, not promotional targets. A dynamic modeling study in Ireland estimated markedly different eligible populations under alternative international criteria and projected approximately 36,000 annual low-dose CT scans at steady state under one set of assumptions.¹² Those figures belong to Ireland and depend on modeled smoking trends, criteria, and uptake assumptions. The transferable lesson is the planning method: estimate demand, make assumptions visible, and model the downstream work for imaging, result communication, nodule review, diagnostic procedures, pathology, navigation, and treatment readiness before expanding outreach.

The pathway must also be designed for equity. A large U.S. retrospective database study found modest racial and ethnic differences in distant-stage lung cancer presentation after adjustment.² An Ontario population analysis associated stage at diagnosis and receipt of surgery with primary-care attachment, income, age, comorbidity, and other factors.⁷ These studies do not establish that any one characteristic caused an individual outcome. They challenge organizations to measure where access, diagnostic follow-up, navigation, geography, and structural barriers differ across populations.

A useful executive promise is bounded and testable: for one defined lung cancer pathway, every active case will have an accountable owner, a current status, a next action, a due date or review point, and a visible exception route. The promise begins at the chosen entry point and continues until the intended next step is completed or a documented alternative is communicated. It should include people who decline or defer, because respect for choice does not remove the need for clear information, documented disposition, and a safe route back into care.

World Lung Cancer Day provides a reason to convene the full pathway, including patients, caregivers, community partners, primary care, radiology, pulmonology, pathology, surgery, medical and radiation oncology, pharmacy, palliative and supportive care, informatics, finance, access services, and quality teams. The observance is successful when it produces an owned improvement commitment, not when it produces only a temporary message.

A lung cancer pathway should be mapped from the perspective of the person moving through it. The person does not experience separate departments. They experience a series of decisions, waits, explanations, tests, travel demands, costs, and transitions. A dependable design makes the next step clear at each point and prevents the case from becoming invisible when responsibility changes.

The first stage includes more than finding names in a registry. The organization must define which population the program serves, which clinical standards apply, who reviews exceptions, and how people receive balanced information. A 2026 analysis of 16 risk-prediction models across U.S. racial and ethnic groups found that model performance varied and should not be assumed to transfer uniformly.³ Risk prediction can support structured assessment, but model outputs require local clinical governance, validation awareness, and equity review.

The second stage should convert a decision into a scheduled action without forcing the patient to become the coordinator. Orders should not wait in private work queues without visibility. Authorization requests, prior imaging, clinical documentation, transportation, and language needs should be assigned. If the patient does not schedule, the pathway needs a defined response that distinguishes an informed decision to defer from an operational failure to connect.

The third and fourth stages are where many programs lose sight of the case. A report is not closed because it was signed. It is closed when the authorized recipient has reviewed it, the person has received an understandable communication, the next action is assigned, and the planned follow-up is traceable. Incidental findings need their own governance so they are neither ignored nor allowed to create unbounded work without prioritization. A European expert survey rated management of incidental findings, guideline-based nodule management, and communication among the most important competencies for low-dose CT screening.⁶ The survey is small and descriptive, but it supports training across the full workflow.

The fifth and sixth stages combine diagnostic strategy with tissue stewardship. The least invasive feasible biopsy route may sometimes provide adequate tissue for diagnosis, staging, PD-L1 assessment, and genomic profiling, but that determination is patient-specific. A prospective-cohort analysis reported high diagnostic and molecular-testing yields from ultrasound-guided sampling of accessible superficial metastases in one advanced lung cancer population.⁸ It does not establish superiority for every case. It supports multidisciplinary review before a procedure, with adequacy for downstream testing included in the decision.

The final stage includes treatment readiness, supportive and palliative care, symptom management, caregiver communication, surveillance, and a route back when plans change. A pathway is not complete when the tumor board recommends an option. It is complete when the person can reach the next agreed step, unresolved barriers are assigned, and changes in goals or condition are incorporated. Supportive care should not be framed as a failure of disease-directed treatment. It is part of high-quality lung cancer care across the trajectory.

Once a finding requires diagnostic work, the pathway becomes more complex. Imaging review, bronchoscopy, percutaneous biopsy, surgery, pathology, molecular diagnostics, staging, and oncology planning may interact. The safest approach is not to impose one sequence from an executive office. It is to ensure that qualified clinicians can see the relevant information, coordinate the procedure and tissue goals, and recover when the first plan does not yield what the next decision requires.

A contemporary review describes the expanding role of pulmonologists in lung cancer care, including diagnosis, mediastinal staging, tissue stewardship, therapeutic bronchoscopy, nodule programs, and longitudinal pulmonary support.⁵ As a narrative review, it does not produce one effect estimate. It supports multidisciplinary operating design. Leaders should make space for coordinated planning rather than expecting separate services to optimize the pathway through messages sent after decisions are made.

Procedure planning should include a clear diagnostic objective, staging needs, expected tissue requirements, available modalities, patient preferences, comorbidities, and contingency options. The prospective-cohort analysis of ultrasound-guided sampling found high reported yields for histologic diagnosis, comprehensive genomic profiling, and PD-L1 testing in a selected advanced-cancer population with accessible superficial metastases.⁸ These results are encouraging but do not make that technique appropriate for every person. The executive lesson is to measure adequacy and repeat-procedure burden, and to support pre-procedure coordination.

Biomarker testing is a handoff system. In a retrospective community-oncology study, 80% of patients with metastatic non-small cell lung cancer received biomarker testing, and the median interval from diagnosis to first test order was 10 days. Actionable alterations were reported in 29% of tested NSCLC cases. Some patients began treatment before results were available and later changed therapy following a positive result.⁴ The single-network, retrospective design and industry funding limit generalizability. The findings identify measurable workflow questions: Was tissue sufficient? Was testing ordered at the intended point? Did authorization delay it? When was the specimen received? When were results complete? Who saw them? Was the plan reviewed before treatment started?

Pathology status should be visible without exposing protected information more broadly than necessary. An active-case view might show specimen received, adequacy under review, indicated tests ordered, outside material requested, estimated completion, exception reason, and accountable owner. It should not display sensitive detail to people who do not need it. Privacy and role-based access must be designed with informatics and compliance teams.

Tissue stewardship includes avoiding preventable repetition while preserving clinical choice. A repeat procedure may be necessary because disease biology, anatomy, safety, or testing needs change. The improvement question is whether the need was recognized early, the rationale was documented, the patient received an understandable explanation, and the pathway avoided delays caused by missing information or uncoordinated orders. Repeat-procedure rate alone is not a quality verdict.

Multidisciplinary review should have a purpose and a closure method. A conference can bring expertise together but still fail if recommendations are not documented, responsible owners are unclear, or access barriers are discovered afterward. Each reviewed case should leave with a recorded disposition, unresolved questions, owners, and a next review point. When evidence is incomplete or patient preferences require further discussion, uncertainty should remain visible rather than forced into a false final answer.

Treatment readiness is broader than a pathology report. It may include prior authorization, pharmacy preparation, radiation planning, surgical evaluation, medical optimization, transportation, caregiver planning, symptom control, fertility or other counseling when relevant, clinical trial review, and goals-of-care discussion. Leaders should measure the interval components they can improve without turning complex clinical decisions into a race against a single universal clock.

Capacity planning should follow the whole pathway. Screening growth can increase radiology volume, comparison-image requests, nodule-review work, patient communication, surveillance, procedures, pathology, molecular testing, tumor-board cases, oncology visits, supportive-care demand, and navigation. If leaders plan only the first service, bottlenecks move to the next stage and remain invisible until patients wait.

The Ireland modeling study demonstrates why alternative eligibility criteria create different workload estimates.¹² Local programs should build scenarios for invitation volume, expected response, screening completion, positive and indeterminate findings, incidental findings, diagnostic procedures, repeat procedures, and treatment-ready cases. Every assumption should have a source, range, owner, and review date. A model is a planning instrument, not a promise of actual volume.

Capacity also includes workforce competence. The European survey found heterogeneous training arrangements and identified incidental-finding management, nodule guidance, communication, and basic AI knowledge as priorities.⁶ Because the survey included only 25 experts, it cannot define a universal curriculum. It suggests that implementation teams should assess the actual competencies required at each handoff and provide role-specific practice, escalation support, and feedback.

Operational redesign can create capacity, but reported gains require cautious interpretation. A single-center Bulgarian implementation study used observation, interviews, process mapping, time-driven activity-based costing, multidisciplinary meetings, a call center, and partial patient-reported outcome measurement. The center reported that day-hospital capacity increased from 50 to 100 patients per day after one year.¹⁴ Without a control group, the study cannot attribute all changes to the intervention. It illustrates how leaders can examine administrative work, role design, referrals, and patient-reported information as part of capacity rather than assuming that clinicians must simply work faster.

Resilience is the ability to protect essential steps during disruption. A 2026 systematic review of 78 studies found that the COVID-19 pandemic was associated in many settings with reductions in lung cancer screening, follow-up, diagnostic procedures, and newly diagnosed cases. Most studies reported an average decline of approximately 20% in new diagnoses, but results varied, and some studies reported opposite stage patterns.⁹ The approximate figure is not a universal benchmark. The review supports preparedness for maintaining result closure, triage, diagnostic access, and communication when normal operations change.

A resilience plan should identify the minimum functions that must continue, the people who can authorize prioritization, backup coverage, communication methods, and the thresholds for executive escalation. It should address imaging interruptions, staffing shortages, pathology downtime, supply constraints, cyber incidents, severe weather, transportation disruption, and sudden demand. The plan should protect privacy and clinical authority while making operational tradeoffs explicit.

Diagnostic-resolution capacity deserves its own review because delay can be produced by many queues. Decompose time from abnormal result to clinical review, review to referral, referral to acceptance, acceptance to consultation, consultation to procedure, procedure to pathology, pathology to required molecular completion, and readiness to treatment start. Do not convert every interval into a punitive target. Use decomposition to find where cases become unowned and where demand exceeds available capacity.

Workforce burden should be treated as a system condition. Repeated manual reconciliation, searching for outside records, chasing authorizations, and answering the same status question consume skilled time. Leaders should identify work that can be standardized, automated with appropriate governance, reassigned, or eliminated. A new dashboard that creates duplicate entry is not an improvement. Any technology should be tested for accuracy, access, privacy, workflow fit, bias, and failure recovery.

Capacity decisions should preserve a balance between access and safety. Extended hours, added procedural sessions, centralized review, or remote support may help, but each requires staffing, supervision, equipment, recovery space, transport, and fatigue controls. The question is not only how much capacity can be added. It is whether the entire pathway can safely absorb and close the additional work.

A 90-day cycle is long enough to define one pathway, collect a credible baseline, listen to people who experience the handoffs, test a small package, and review early performance. It is not long enough to prove mortality benefit, eliminate structural inequity, or validate a model for every population. The purpose is to improve the operating conditions that leaders can directly influence while preserving clinical authority and evidence limits.

During days 1 through 30, define the pathway narrowly. A useful scope might be annual repeat screening after a normal result, suspicious findings from one imaging site, nodules referred from three primary-care practices, or biomarker completion for newly diagnosed metastatic non-small cell lung cancer. State the start and end points, population, exclusions, clinical owner, operational owner, and partners. A narrow pathway makes ownership and measurement possible.

Map real cases, not only the policy. Trace one smooth journey, one scheduling failure, one abnormal result with delay, one case requiring tissue and molecular testing, one patient who declined or deferred, and one exception that the team successfully recovered. Protect privacy and separate operational defects from patient preference and clinical judgment. Note where the case changes identity across systems and where information is re-entered.

Listen before selecting the intervention. Patients and caregivers can identify unclear language, stigma, travel, digital friction, financial concerns, and uncertainty. Primary-care teams can describe order and result burden. Radiology can identify reporting and incidental-finding work. Pulmonology and pathology can identify tissue and staging dependencies. Navigators can show where the system relies on manual rescue. Community partners can explain why apparently convenient outreach fails in practice.

Build a small baseline. Count the defined population, current dispositions, active orders, completed scans, uncommunicated results, abnormal results without completed next action, diagnostic queues, tissue adequacy, pending molecular work, and active cases without owners. Decompose a few intervals and stratify only where the data can be interpreted safely. Annotate missing data rather than treating absence as performance.

During days 31 through 60, test a package rather than a message. The package might include a due-list review, clinician order support, patient outreach in preferred modes, escalation for nonresponse, a shared abnormal-result queue, an accepted-referral confirmation, a tissue-readiness checklist owned by authorized teams, and a molecular-testing status view. Each element needs an owner, backup, review cadence, and failure route.

Use the evidence as a boundary. The Larch trial supports testing multilevel reminders, not promising its effect size.¹ The biopsy cohort supports discussing accessible sites and adequacy, not prescribing a procedure.⁸ The biomarker study supports measuring order and turnaround stages, not treating its single-network rates as universal standards.⁴ The capacity and equity studies support questions that local data and clinical teams must answer.

Test recovery from exceptions. What happens when a patient cannot use the portal, an address is stale, authorization is denied, outside images do not arrive, a referral is declined, the intended procedure is unavailable, tissue is insufficient, molecular testing is delayed, or transportation fails? Reliability is not the absence of variation. It is the ability to detect, assign, escalate, communicate, and recover.

During days 61 through 90, verify the controls in actual work. Check whether the active-case view is current, whether staff understand the definitions, whether patients can identify the next step, whether backup coverage works, whether results close, and whether one improvement created a new bottleneck. Review both favorable and unfavorable cases. A process that works only when one expert is present is not yet reliable.

The executive review should make one of four decisions. Sustain when the design is usable, owned, resourced, and supported by local evidence. Adapt when the purpose is sound but the workflow remains fragile. Stop when the change adds burden or risk without addressing the defect. Study further when uncertainty is material. Document the reasoning and the evidence limits.

Spread is a new implementation decision. Another site or population may have different technology, language needs, referral relationships, transportation, staffing, or community trust. The spread package should state its purpose, required governance, adaptable components, definitions, resources, and conditions that require new clinical review. Copying a dashboard or checklist without the relationships that sustain it can create the appearance of control without continuity.